PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer
Table 2
Survival analyses of PCMT1 with different molecular subtypes based on the 2013 St. Gallen criteria in breast cancer.
BRCA subtype
Survival outcome
205202_at
208857_s_at
210156_s_at
HR (95% CI)
HR (95% CI)
HR (95% CI)
Basal-like
RFS
1.12 (0.89-1.4)
0.34
0.9 (0.71-1.14)
0.38
0.92 (0.74-1.15)
0.47
OS
1.3 (0.84-2)
0.23
0.63 (0.43-0.94)
0.022
0.6 (0.41-0.88)
0.0084
DMFS
0.73 (0.52-1.03)
0.071
0.69 (0.5-0.94)
0.018
0.86 (0.62-1.21)
0.39
PPS
1.39 (0.73-2.64)
0.31
0.55 (0.31-0.95)
0.029
0.72 (0.41-1.28)
0.26
Luminal A
RFS
1.43 (1.21-1.69)
2.7e-05
1.64 (1.38-1.95)
1.1e-08
1.23 (1.04-1.47)
0.019
OS
1.94 (1.41-2.67)
3.9e-05
2.04 (1.48-2.81)
8.5e-06
1.34 (0.97-1.85)
0.075
DMFS
1.32 (1.02-1.71)
0.036
1.63 (1.24-2.15)
0.00045
1.34 (1.02-1.76)
0.038
PPS
1.78 (1.24-2.55)
0.0014
2.24 (1.55-3.24)
1.2e-05
0.75 (0.51-1.09)
0.13
Luminal B
RFS
1.4 (1.13-1.72)
0.0017
1.52 (1.28-1.82)
2.5e-06
1.37 (1.15-1.64)
0.0004
OS
1.42 (0.93-2.19)
0.1
1.51 (1.06-2.14)
0.02
1.27 (0.85-1.9)
0.24
DMFS
0.83 (0.61-1.15)
0.26
0.82 (0.62-1.1)
0.18
1.19 (0.88-1.6)
0.26
PPS
1.7 (0.99-2.93)
0.053
1.3 (0.85-2.27)
0.19
0.86 (0.56-1.31)
0.49
HER2+
RFS
1.31 (0.88-1.96)
0.19
0.67 (0.44-1.02)
0.063
0.72 (0.5-1.04)
0.075
OS
0.8 (0.44-1.45)
0.47
0.51 (0.25-1.06)
0.066
0.51 (0.26-0.99)
0.044
DMFS
0.48 (0.24-0.97)
0.037
0.48 (0.24-0.89)
0.019
0.59 (0.35-1.02)
0.055
PPS
1.51 (0.57-3.98)
0.4
0.58 (0.25-1.38)
0.21
0.57 (0.24-1.35)
0.19
HR: hazard ratio; CI: confidence interval; RFS: relapse free survival; OS: overall survival; DMFS: distant metastasis-free survival; PPS: postprogression survival. All of the data above were obtained from the Kaplan–Meier Plotter database. The data with statistical significance () were marked in bold text.
